In addition, selpercatinib has been shown to have greater efficacy in phase III trials over standard-of-care therapy, with an overall response rate of 69.4 versus 38.8% in controls for patients with RET-positive MTC (Hadoux et al. 2023). Here, RET is linked to medullary thyroid gland carcinoma.